These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1875 related articles for article (PubMed ID: 17021319)

  • 1. Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
    Brown DM; Kaiser PK; Michels M; Soubrane G; Heier JS; Kim RY; Sy JP; Schneider S;
    N Engl J Med; 2006 Oct; 355(14):1432-44. PubMed ID: 17021319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
    Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
    Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
    Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
    Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
    Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ranibizumab for neovascular age-related macular degeneration.
    Rosenfeld PJ; Brown DM; Heier JS; Boyer DS; Kaiser PK; Chung CY; Kim RY;
    N Engl J Med; 2006 Oct; 355(14):1419-31. PubMed ID: 17021318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results.
    Antoszyk AN; Tuomi L; Chung CY; Singh A;
    Am J Ophthalmol; 2008 May; 145(5):862-74. PubMed ID: 18321465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Bressler NM; Chang TS; Fine JT; Dolan CM; Ward J;
    Arch Ophthalmol; 2009 Jan; 127(1):13-21. PubMed ID: 19139332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration.
    Vallance JH; Johnson B; Majid MA; Banerjee S; Mandal K; Bailey CC
    Eye (Lond); 2010 Oct; 24(10):1561-7. PubMed ID: 20577273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results.
    Kaiser PK; Brown DM; Zhang K; Hudson HL; Holz FG; Shapiro H; Schneider S; Acharya NR
    Am J Ophthalmol; 2007 Dec; 144(6):850-857. PubMed ID: 17949673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
    Spielberg L; Leys A
    Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Kaiser PK; ; Boyer DS; Garcia R; Hao Y; Hughes MS; Jabbour NM; Kaiser PK; Mieler W; Slakter JS; Samuel M; Tolentino MJ; Roth D; Sheidow T; Strong HA
    Ophthalmology; 2009 Apr; 116(4):747-55, 755.e1. PubMed ID: 19243834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2014 Aug; 8(8):CD005139. PubMed ID: 25170575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.
    Arch Ophthalmol; 1999 Oct; 117(10):1329-45. PubMed ID: 10532441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab.
    Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J
    Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
    Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
    Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
    Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
    Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial.
    Azab M; Boyer DS; Bressler NM; Bressler SB; Cihelkova I; Hao Y; Immonen I; Lim JI; Menchini U; Naor J; Potter MJ; Reaves A; Rosenfeld PJ; Slakter JS; Soucek P; Strong HA; Wenkstern A; Su XY; Yang YC;
    Arch Ophthalmol; 2005 Apr; 123(4):448-57. PubMed ID: 15824216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.